A Clinical Evaluation of Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression
Primary Purpose
Treatment Resistant Depression, Depressive Disorder
Status
Unknown status
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Libra Deep Brain Stimulation System
Sponsored by
About this trial
This is an interventional treatment trial for Treatment Resistant Depression focused on measuring major depressive disorder (MDD), deep brain stimulation (DBS), subcallosal cingulate gyrus, Therapy-Resistant Depression, Electrical Stimulation of the Brain, Brain Stimulation, Deep
Eligibility Criteria
Inclusion Criteria:
- Men and women (non-pregnant) ages 21-70 years;
- Diagnosed with non-psychotic major depressive disorder, single or recurrent episode by DSM-IV-TR criteria;
- First episode onset before age 45;
- Current episode > 12 months duration;
- In the current episode: Documented resistance (i.e. persistence of the major depressive episode) to a minimum of 4 adequate depression treatments from at least 3 different treatment categories (e.g. SSRI's, SNRI's, TCA's, MAO-inhibitors, Mirtazipine, Nefazodone, Trazodone, Bupropion, lithium augmentation, thyroid augmentation, ECT); Adequacy of treatments as defined by a score of at least 3 according to the amended Antidepressant Treatment History Form (ATHF) criteria;
- Hamilton Depression Rating Scale (HDRS) of > 20 at 3 separate baseline visits, rated by 2 separate psychiatrists, Baseline 2 and Baseline 3 HDRS scores cannot improve ≥ 25%;
Exclusion Criteria:
- A diagnosis of a bipolar I or bipolar II disorder by DSM-IV-TR criteria;
- Meets criteria for borderline or antisocial personality disorder in the last 12 months by DSM-IV-TR criteria, derived from the Cluster B Personality.
- In the current depressive episode, has been diagnosed with General Anxiety Disorder (GAD) - as defined by the DSM-IV-TR, and GAD is the primary diagnosis;
- Has an intracranial Central Nervous System (CNS) disease that impairs motor, sensory or cognitive function or that requires intermittent or chronic medication (e.g., Parkinson's Disease, migraine, stroke, Huntington's, head trauma, etc.) with exception to non-migraine headaches;
- Has been diagnosed with fibromyalgia or has a current condition which requires chronic pain narcotic usage (e.g. morphine, methadone);
- Has been currently diagnosed with chronic fatigue syndrome;
- Substantial suicidal risk as defined by (1) a current plan and intent, (2) clinician judgment that there is a clear immediate intent for self-harm, (3) more than 3 suicide attempts within the last 12 months;
- Co-morbid obsessive compulsive disorder, post-traumatic stress disorder, panic disorder, bulimia or anorexia nervosa if previously present, must be in remission for 6 months as defined by DSM-IV-TR criteria, derived from the MINI;
- Alcohol, medication, or illegal substance dependence within last 12 months;
- Advanced cardiovascular disease which renders anesthesia and surgery as unsafe as determined by neurosurgeon;
- Plans to use diathermy;
- Have any metallic implants in the brain such as aneurysm clips or cochlear implants;
- Currently participating in another investigational device, drug or surgical trial.
Sites / Locations
- Toronto General Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Sham Comparator
Arm Label
Stimulation
No Stimulation
Arm Description
Libra Deep Brain Stimulation System is implanted and activated post implantation
The Libra DBS System is implanted and not activated
Outcomes
Primary Outcome Measures
Primary Efficacy: Changes in the Hamilton Depression Rating Scale-17
evaluate change in HAMD-17 3 months and 6 months after implantation
Secondary Outcome Measures
The incidence of all adverse events
The incidence of all adverse events (i.e. hospitalization due to worsening depression, suicidal ideation, or behavior, medical treatment, and device related events) that occur over study duration.
Showing SCG-DBS significantly increases health related quality of life compared to sham stimulation in patients with TRD
The following health related quality of life measures will be evaluated: Sheehan Disability Scale-Visual Analog Scale (SDS-VAS), Short Form-12 (SF-12), Sexual Functioning questionnaire (SEX FX) and Endicott Work Productivity Scale (EWPS). Each measure will be evaluated at baseline and the after each treatment period.
Full Information
NCT ID
NCT01801319
First Posted
February 26, 2013
Last Updated
April 24, 2017
Sponsor
Abbott Medical Devices
1. Study Identification
Unique Protocol Identification Number
NCT01801319
Brief Title
A Clinical Evaluation of Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression
Official Title
A Clinical Evaluation of Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression
Study Type
Interventional
2. Study Status
Record Verification Date
April 2017
Overall Recruitment Status
Unknown status
Study Start Date
June 2011 (undefined)
Primary Completion Date
June 2017 (Anticipated)
Study Completion Date
December 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Abbott Medical Devices
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a randomized, placebo-controlled double-blind cross-over trial evaluating the safety, efficacy, daily functioning, and health-related quality of life of Subcallosal Cingulate Gyrus Deep Brain Stimulation (SCG DBS) for participants with Treatment-Resistant Depression (TRD). A total of 40 eligible participants will be randomized to four treatment sequences (10 participants per sequence). Each participant will be treated over a 6-month period with active or sham stimulation in which both the participants and the attending psychiatrists will be blinded to treatment allocation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Treatment Resistant Depression, Depressive Disorder
Keywords
major depressive disorder (MDD), deep brain stimulation (DBS), subcallosal cingulate gyrus, Therapy-Resistant Depression, Electrical Stimulation of the Brain, Brain Stimulation, Deep
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Non-Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Stimulation
Arm Type
Active Comparator
Arm Description
Libra Deep Brain Stimulation System is implanted and activated post implantation
Arm Title
No Stimulation
Arm Type
Sham Comparator
Arm Description
The Libra DBS System is implanted and not activated
Intervention Type
Device
Intervention Name(s)
Libra Deep Brain Stimulation System
Primary Outcome Measure Information:
Title
Primary Efficacy: Changes in the Hamilton Depression Rating Scale-17
Description
evaluate change in HAMD-17 3 months and 6 months after implantation
Time Frame
3 and 6 months
Secondary Outcome Measure Information:
Title
The incidence of all adverse events
Description
The incidence of all adverse events (i.e. hospitalization due to worsening depression, suicidal ideation, or behavior, medical treatment, and device related events) that occur over study duration.
Time Frame
6 months
Title
Showing SCG-DBS significantly increases health related quality of life compared to sham stimulation in patients with TRD
Description
The following health related quality of life measures will be evaluated: Sheehan Disability Scale-Visual Analog Scale (SDS-VAS), Short Form-12 (SF-12), Sexual Functioning questionnaire (SEX FX) and Endicott Work Productivity Scale (EWPS). Each measure will be evaluated at baseline and the after each treatment period.
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Men and women (non-pregnant) ages 21-70 years;
Diagnosed with non-psychotic major depressive disorder, single or recurrent episode by DSM-IV-TR criteria;
First episode onset before age 45;
Current episode > 12 months duration;
In the current episode: Documented resistance (i.e. persistence of the major depressive episode) to a minimum of 4 adequate depression treatments from at least 3 different treatment categories (e.g. SSRI's, SNRI's, TCA's, MAO-inhibitors, Mirtazipine, Nefazodone, Trazodone, Bupropion, lithium augmentation, thyroid augmentation, ECT); Adequacy of treatments as defined by a score of at least 3 according to the amended Antidepressant Treatment History Form (ATHF) criteria;
Hamilton Depression Rating Scale (HDRS) of > 20 at 3 separate baseline visits, rated by 2 separate psychiatrists, Baseline 2 and Baseline 3 HDRS scores cannot improve ≥ 25%;
Exclusion Criteria:
A diagnosis of a bipolar I or bipolar II disorder by DSM-IV-TR criteria;
Meets criteria for borderline or antisocial personality disorder in the last 12 months by DSM-IV-TR criteria, derived from the Cluster B Personality.
In the current depressive episode, has been diagnosed with General Anxiety Disorder (GAD) - as defined by the DSM-IV-TR, and GAD is the primary diagnosis;
Has an intracranial Central Nervous System (CNS) disease that impairs motor, sensory or cognitive function or that requires intermittent or chronic medication (e.g., Parkinson's Disease, migraine, stroke, Huntington's, head trauma, etc.) with exception to non-migraine headaches;
Has been diagnosed with fibromyalgia or has a current condition which requires chronic pain narcotic usage (e.g. morphine, methadone);
Has been currently diagnosed with chronic fatigue syndrome;
Substantial suicidal risk as defined by (1) a current plan and intent, (2) clinician judgment that there is a clear immediate intent for self-harm, (3) more than 3 suicide attempts within the last 12 months;
Co-morbid obsessive compulsive disorder, post-traumatic stress disorder, panic disorder, bulimia or anorexia nervosa if previously present, must be in remission for 6 months as defined by DSM-IV-TR criteria, derived from the MINI;
Alcohol, medication, or illegal substance dependence within last 12 months;
Advanced cardiovascular disease which renders anesthesia and surgery as unsafe as determined by neurosurgeon;
Plans to use diathermy;
Have any metallic implants in the brain such as aneurysm clips or cochlear implants;
Currently participating in another investigational device, drug or surgical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sidney Kennedy, M.D.
Organizational Affiliation
Toronto General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Toronto General Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2C4
Country
Canada
12. IPD Sharing Statement
Learn more about this trial
A Clinical Evaluation of Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression
We'll reach out to this number within 24 hrs